Pancreatic Cancer Research

Clinical trialNo phase (not a drug trial)Recruiting

Stereotactic Magnetic Resonance Guided Radiation Therapy

A Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)

Outcome
Ongoing
Phase
No phase (not a drug trial)
Status
Recruiting
Study type
Interventional
Start
22 October 2019
Expected end
June 2028
Enrollment
397 participants
Sites
2
Primary outcomes
Delivery Success Rate for SMART across multiple tumors-Phase I; Tumor visualization-Phase I; Plan creation-Phase I; Rate of Improvement in Tumor Control-Phase II
Sponsor type
Academic / other
Results posted
No
Last update
13 November 2025

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. * The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures

Detailed description public domain (ClinicalTrials.gov)

This research study is a feasibility study, which means it is the first-time investigators at this institution are examining this type of MR-guided radiation to treat cancer. The U.S. Food and Drug Administration (FDA) has approved this device as a treatment option for cancer. In this research study, the investigators are hoping to determine if adjusting radiation treatments based on daily MRI has a feasible way to deliver radiation for participants with pancreatic, lung or renal cancer.